SMYD3 is a member of the histone lysine methyltransferases enzyme family, and upregulates transcription of a plethora of oncogenes in multiple cancer types, including CDK2 and MMP2 in hepatocellular carcinomas (Wang et al,2019), BCLAF1 in bladder cancer (Shen et al,2016), androgen receptors in prostate cancer (Liu et al,2013), EGFR in renal cell carcinoma (Liu et al,2020a), and MYC and CTNNB1 in colon and liver cancers (Sarris et al,2016). Here, SMYD3 is linked to hereditary clear cell renal cell carcinoma.